Raking in profits, Moderna denies government scientists credit for the COVID vaccine
While much of the world was sent into a panic by the sudden emergence of the Omicron variant of the coronavirus, Moderna Inc. weathered the shock pretty well. Indeed, its shares have gained more than 25% in value since the World Health Organization labeled the microbe a “variant of concern” and gave it a Greek-letter designation Friday. But all is not bright for Moderna. Thanks in part to the astounding success of its vaccine, the company is also locked in a fierce battle with the U.S. government over credit for developing the vaccine.